Moomoo AI 已提取核心訊息
Alterity Therapeutics Limited, a development stage enterprise, has announced a security purchase plan (SPP Offer) to raise up to $2 million before costs. The SPP Offer includes the issue of up to 571,428,571 fully paid ordinary shares (SPP Shares) at $0.0035 per share, with one free-attaching option for each SPP Share issued, expiring on August 31, 2024 (Short Dated Options), and one free-attaching option for every three SPP Shares issued, expiring on August 31, 2026 (Long Dated Options). Eligible Shareholders may apply for a maximum of 8,571,429 SPP Shares ($30,000), with the offer opening on January 10, 2024, and closing on January 25, 2024. The SPP Offer is not underwritten and is available only to shareholders with registered addresses in Australia and New Zealand. The funds raised will support clinical trials, research efforts in neurodegenerative diseases, and general working capital. The SPP Shares and options are considered speculative investments.
Alterity Therapeutics Limited, a development stage enterprise, has announced a security purchase plan (SPP Offer) to raise up to $2 million before costs. The SPP Offer includes the issue of up to 571,428,571 fully paid ordinary shares (SPP Shares) at $0.0035 per share, with one free-attaching option for each SPP Share issued, expiring on August 31, 2024 (Short Dated Options), and one free-attaching option for every three SPP Shares issued, expiring on August 31, 2026 (Long Dated Options). Eligible Shareholders may apply for a maximum of 8,571,429 SPP Shares ($30,000), with the offer opening on January 10, 2024, and closing on January 25, 2024. The SPP Offer is not underwritten and is available only to shareholders with registered addresses in Australia and New Zealand. The funds raised will support clinical trials, research efforts in neurodegenerative diseases, and general working capital. The SPP Shares and options are considered speculative investments.
處於開發階段的企業Alterity Therapeutics Limited宣佈了一項證券購買計劃（SPP報價），將在不計成本的情況下籌集高達200萬美元的資金。SPP要約包括以每股0.0035美元的價格發行最多571,428,571股已全額支付的普通股（SPP股票），每發行一份將於2024年8月31日到期的免費附加期權（短期期權），以及每三股SPP股票的自由附加期權，將於2026年8月31日到期（遠期期權）。符合條件的股東最多可以申請8,571,429股SP股票（合3萬美元），要約將於2024年1月10日開始，並於2024年1月25日結束。SPP要約不承保，僅適用於註冊地址在澳大利亞和新西蘭的股東。籌集的資金將用於支持臨床試驗、神經退行性疾病的研究工作和一般營運資金。SPP股票和期權被視爲投機性投資。
處於開發階段的企業Alterity Therapeutics Limited宣佈了一項證券購買計劃（SPP報價），將在不計成本的情況下籌集高達200萬美元的資金。SPP要約包括以每股0.0035美元的價格發行最多571,428,571股已全額支付的普通股（SPP股票），每發行一份將於2024年8月31日到期的免費附加期權（短期期權），以及每三股SPP股票的自由附加期權，將於2026年8月31日到期（遠期期權）。符合條件的股東最多可以申請8,571,429股SP股票（合3萬美元），要約將於2024年1月10日開始，並於2024年1月25日結束。SPP要約不承保，僅適用於註冊地址在澳大利亞和新西蘭的股東。籌集的資金將用於支持臨床試驗、神經退行性疾病的研究工作和一般營運資金。SPP股票和期權被視爲投機性投資。
有用
沒用